Wuhan Keqian Biology Co.,Ltd (SHA:688526)

SHA:688526 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	1,005	933.04	1,027	974.14	1,083	835
Other Revenue	8.88	8.88	37.14	27.12	19.86	8.23
Revenue	1,014	941.92	1,064	1,001	1,103	843.23
Revenue Growth (YoY)	12.43%	-11.48%	6.27%	-9.22%	30.81%	66.15%
Cost of Revenue	364.7	360.45	321.43	279.05	230.42	151.17
Gross Profit	649.58	581.48	742.65	722.22	872.6	692.06
Selling, General & Admin	159.99	169.4	213.2	219.26	201.91	153.06
Research & Development	96.84	86.12	88.51	102.75	80	59.08
Other Operating Expenses	4.86	-0.93	-0.82	6.29	5.92	3.95
Operating Expenses	237.95	266.47	385.36	339.01	296.9	223.43
Operating Income	411.62	315.01	357.29	383.21	575.71	468.63
Interest Expense	-0.49	-4.77	-8.16	-5.45	-1.81	-0.43
Interest & Investment Income	56.61	73.17	94.12	75.69	71.86	37.32
Currency Exchange Gain (Loss)	0	0	0.05	-	-	-
Other Non Operating Income (Expenses)	-0.87	-0.72	-0.21	-0.2	-0.27	-0.36
EBT Excluding Unusual Items	466.87	382.69	443.1	453.25	645.48	505.16
Impairment of Goodwill	-3.31	-3.31	-	-	-	-
Gain (Loss) on Sale of Investments	31.86	30.99	-10.19	1.44	-	-
Gain (Loss) on Sale of Assets	-0.75	0.93	-	-	-	-0.59
Asset Writedown	8.84	-0.53	-1.72	-0.14	-1.57	-
Legal Settlements	-	-	-	-	0.82	-2.78
Other Unusual Items	26.78	27.36	26.39	12.06	15.32	17.87
Pretax Income	530.29	438.13	457.58	466.61	660.05	519.66
Income Tax Expense	72.21	56.64	62	57.46	89.41	71.86
Earnings From Continuing Operations	458.09	381.49	395.58	409.15	570.64	447.8
Minority Interest in Earnings	1.45	0.86	0.35	0.37	0.11	-
Net Income	459.54	382.35	395.93	409.52	570.74	447.8
Net Income to Common	459.54	382.35	395.93	409.52	570.74	447.8
Net Income Growth	53.64%	-3.43%	-3.32%	-28.25%	27.45%	84.55%
Shares Outstanding (Basic)	469	466	466	465	464	386
Shares Outstanding (Diluted)	469	466	466	465	464	386
Shares Change (YoY)	0.52%	0.10%	0.10%	0.29%	20.20%	6.59%
EPS (Basic)	0.98	0.82	0.85	0.88	1.23	1.16
EPS (Diluted)	0.98	0.82	0.85	0.88	1.23	1.16
EPS Growth	52.84%	-3.53%	-3.41%	-28.46%	6.03%	73.13%
Free Cash Flow	314.49	285.74	433.53	320.86	156.82	288.54
Free Cash Flow Per Share	0.67	0.61	0.93	0.69	0.34	0.75
Dividend Per Share	0.430	0.430	0.430	0.190	0.190	0.290
Dividend Growth	-	-	126.32%	-	-34.48%	-
Gross Margin	64.04%	61.73%	69.79%	72.13%	79.11%	82.07%
Operating Margin	40.58%	33.44%	33.58%	38.27%	52.19%	55.58%
Profit Margin	45.31%	40.59%	37.21%	40.90%	51.74%	53.11%
Free Cash Flow Margin	31.01%	30.34%	40.74%	32.05%	14.22%	34.22%
EBITDA	516.09	423.23	470.54	480.16	638.35	505.66
EBITDA Margin	50.88%	44.93%	44.22%	47.95%	57.87%	59.97%
D&A For EBITDA	104.46	108.22	113.24	96.95	62.64	37.03
EBIT	411.62	315.01	357.29	383.21	575.71	468.63
EBIT Margin	40.58%	33.44%	33.58%	38.27%	52.19%	55.58%
Effective Tax Rate	13.62%	12.93%	13.55%	12.31%	13.55%	13.83%
Revenue as Reported	1,014	941.92	1,064	1,001	1,103	843.23
Advertising Expenses	-	25.7	34.1	2.87	2.96	5.49

Source: S&P Global Market Intelligence. Standard template. Financial Sources.